Company intelligence / Profile preview

GB002, Inc.

San Diego, California, United Statesir.gossamerbio.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Currently conducting the PROSERA Study, a global registrational Phase 3 clinical trial in patients with WHO Functional Class II and III PAH. Topline results expected in Q4 2025. Also planning to commence a Phase 3 trial for PH-ILD in mid-2025.

Therapeutic areas: PulmonologyCardiovascular
Modalities: Small molecules (inhaled PDGFR, CSF1R, and c-KIT inhibitor)
Industry: Biotech

Drug pipeline

1 asset

seralutinib

Phase 3

Indications: Pulmonary arterial hypertension, Pulmonary hypertension associated with interstitial lung disease

Partnerships

Pulmokine, Inc. (license agreement for GB002)

Beyond the preview

Go deeper on GB002, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB002, Inc..

Explore the full profile